Cellectis Inc.

Please stand by, your program is about to begin. Good morning, everyone, and welcome to the Celletics third quarter 2024 earnings call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. Please be aware that today's conference call is being recorded. I would now like to introduce the first speaker, Arthur Stril, Chief Financial Officer. You may begin.

Good morning and welcome everyone to SELECTIS Third Quarter 2024 Business Update and Financial Results Conference Call. Joining me on the call today are Dr. Andre Choulika, our Chief Executive Officer, and Dr. Adrian Kilcoyne, our Chief Medical Officer. Yesterday evening, Selectis issued a 6K and press release reporting our financial statements for the nine-month period ended September 30, 2024, and a business update. The report and press release are available on our website at selectis.com. As a reminder, we will make statements regarding Selectis' financial outlook, including the sufficiency of cash-to-fund operations, in addition to its manufacturing, regulatory, and product development status, as well as product development status of its licensed partners. These forward statements, which are based on our management's current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners, are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 20-F filed with the Security Exchange Commission, SEC, and the financial report, including the management report, for the year ended on December 31, 2023, and subsequent filings Selectis makes with the SEC from time to time. I would now like to turn the call over to Andre.

Thank you, Arthur. Good morning, and thank you, everyone, for joining us today. This quarter, we're excited to announce that research and development activities have started for three programs developed under our collaboration and research agreement with AstraZeneca. One allogenic CAR T for hematological malignancies, one allogenic CAR T for solid tumors, and one in vivo gene therapy for genetic disorders. Selectis is thrilled to have this strategic collaboration with one of the most impressive pharmaceutical companies of the past decade, AstraZeneca. Together, we continue to advance our ambition in cell and gene therapy, bring potentially life-saving therapies to patients with unmet medical needs. In the coming months, we will continue to focus on the enrollment of patients in our core clinical trials, We expect to present phase one data set and large state development strategy in 2025. These programs are key for the company, and in order to focus our resources toward success, we decided to deprioritize the development of Fucar T123, evaluated in relapsed refractory acute myeloid leukemia. We strongly believe that gene-edited cells and gene therapies are revolutionizing medicine across a number of therapeutic areas and will become a large part of molecular medicine of the future. With that, I'd like to turn the call over to Adrian Kilcoyne, our newly appointed chief medical officer. We're thrilled to welcome Adrian to Selectus. He's a strategic, forward-thinking drug developer who is passionate about delivering lifesaving therapies to patients. He joined us at the pivotal time bringing extensive experience in drug development as we're progressing in our core clinical programs. Adrian will give an overview of our clinical trials. Adrian, please go ahead.